Glenmark Pharmaceuticals jumps as its arm inks pact with Hengrui Pharma
Glenmark Pharmaceuticals is currently trading at Rs. 2049.50, up by 31.70 points or 1.57% from its previous closing of Rs. 2017.80 on the BSE.
The scrip opened at Rs. 2043.95 and has touched a high and low of Rs. 2052.00 and Rs. 2023.00 respectively. So far 41061 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 2286.15 on 11-Jul-2025 and a 52 week low of Rs. 1274.70 on 28-Feb-2025.
Last one week high and low of the scrip stood at Rs. 2119.95 and Rs. 2004.30 respectively. The current market cap of the company is Rs. 57879.39 crore.
The promoters holding in the company stood at 46.65%, while Institutions and Non-Institutions held 38.30% and 15.06% respectively.
Glenmark Pharmaceuticals’ wholly owned subsidiary -- Glenmark Specialty S.A. (GSSA) has entered into an exclusive license and collaboration agreement with Hengrui Pharma for Trastuzumab Rezetecan (SHR-A1811), a next-generation HER2-targeting antibody drug conjugate (ADC).
Under the terms of the agreement, Glenmark obtains exclusive rights to develop and commercialize Trastuzumab Rezetecan (SHR-A1811) worldwide, excluding Mainland China, the Hong Kong SAR, the Macao SAR, Taiwan Region, USA, Canada, Europe, Japan, Russia, Armenia, Azerbaijan, Belarus, Kazakhstan, Kyrgyzstan, Moldova, Tajikistan, Turkmenistan and Uzbekistan. Glenmark will pay an upfront payment of $18 million. Hengrui is eligible to receive regulatory and commercial payments of up to $1.093 billion. Based on the net sales of Trastuzumab Rezetecan within the licensed territory, Glenmark will pay corresponding royalties to Hengrui.
Glenmark Pharmaceuticals (Glenmark) is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
